United States - English - NLM (National Library of Medicine)

gland pharma limited - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.  none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data] . the esti

United States - English - NLM (National Library of Medicine)

lifestar pharma llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day).  no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data] . the estimate

Kenya - English - Pharmacy and Poisons Board

laboratory & allied ltd p.o box 42875-00100 nairobi - ephedrine hcl - injection - ephedrine hcl 30mg/ml - cardiac stimulants excluding cardiac glycosides:

United States - English - NLM (National Library of Medicine)

xiromed, llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data ]. the estimated

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryo-fetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data] . the estimate

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - ephedrine hydrochloride - solution for injection - 30 milligram(s)/millilitre - ephedrine

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - chlorphenamine maleate, quantity: 2 mg; pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: purified water; povidone; magnesium stearate; pregelatinised maize starch; erythrosine aluminium lake; microcrystalline cellulose; crospovidone; stearic acid - temporary relief from symptoms of colds and flu.,day tablet: ,temporary relief from the following symptoms: runny nose, nasal congestion, sinus pain, headache, body aches and pain, and fever.,night tablet:,temporary relief from the following symptoms: runny nose, nasal congestion, headache, pain and fever, and sneezing.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - chlorphenamine maleate, quantity: 2 mg; pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; crospovidone; erythrosine; magnesium stearate; povidone; pregelatinised maize starch; purified water; stearic acid - temporary relief of cold and flu symptoms. the day tablets relieve headache, body aches and pains, fever, nasal congestion and runny nose. the night tablets relieve headache, body aches and pains, fever, watery eyes, sneezing, nasal congestion and runny nose.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - chlorphenamine maleate, quantity: 2 mg; pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: purified water; erythrosine aluminium lake; microcrystalline cellulose; pregelatinised maize starch; crospovidone; magnesium stearate; povidone; stearic acid - temporary relief from the following cold & flu symptoms: nasal congestion, sinus pain, runny nose, headache, body aches & pains. reduces fever. the night tablets also provide relief from sneezing and itchy or watery eyes, and assist rest by providing relief from these symptoms.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - ephedrine hydrochloride 10 mg/ml - solution for injection - 10 mg/1 ml - ephedrine hydrochloride 10 mg/ml - adrenergic and dopaminergic agents; r03ca02 ephedrine